Display options
Share it on

J Cancer Res Clin Oncol. 1989;115(2):129-38. doi: 10.1007/BF00397912.

In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminoglutethimide.

Journal of cancer research and clinical oncology

Y de Launoit, R Kiss

Affiliations

  1. Laboratoire d'Histologie, Faculté de Médecine, Université Libre de Bruxelles, Belgium.

PMID: 2469677 DOI: 10.1007/BF00397912

Abstract

We characterized the influence of androstenedione, 5-alpha-dihydrotestosterone and 17-beta-estradiol on the chromatin organization and the cell kinetics (distribution of the cells into the G0-G1, S and G2+ M fractions) of MXT mouse mammary tumors grafted onto animals that were left intact or that were oophorectomized and/or treated with aminoglutethimide. The cell kinetics and chromatin pattern were monitored by analyzing Feulgen-stained MXT imprint smears through a cell image processor, the SAMBA 200 system. We have also assayed the estrogen and progesterone receptors of these MXT tumors, which appeared to possess both of these biological markers. Our results show that ovariectomy or aminoglutethimide treatment slowed down the MXT tumor growth without any additive effect between them. Androstenedione exerted a stimulating influence on the cell kinetics, which were very similar to those observed after estradiol administration; the treatment of castrated animals with aminoglutethimide completely abolished this androstenedione-induced stimulating influence, however. This androgen lacked any apparent efficiency to transform cell nuclei from a state of castration-induced chromatin condensation into a thinly textured and decondensed state, as did estradiol. Dihydrotestosterone was able to activate the cell kinetics of MXT tumor grafted onto castrated animals as well as those of MXT neoplasms grafted on oophorectomized mice treated with aminoglutethimide. Dihydrotestosterone also possesses the property to transform condensed chromatin into decondensed chromatin. It thus appeared that androstenedione and dihydrotestosterone could activate MXT cell proliferation, as did estradiol, although it appeared that their mechanisms of action were quite distinct from each other.

References

  1. Biochem Biophys Res Commun. 1972 May 26;47(4):662-70 - PubMed
  2. Exp Cell Res. 1977 Apr;106(1):119-25 - PubMed
  3. Cancer Res. 1985 Dec;45(12 Pt 1):6010-6 - PubMed
  4. J Natl Cancer Inst. 1985 Jun;74(6):1239-46 - PubMed
  5. J Natl Cancer Inst. 1987 Mar;78(3):573-9 - PubMed
  6. Eur J Cancer. 1980 Nov;16(11):1513-5 - PubMed
  7. Cancer. 1977 Jul;40(1):325-33 - PubMed
  8. Eur J Cancer. 1979 Oct;15(10):1181-4 - PubMed
  9. Steroids. 1975 Oct;26(4):488-500 - PubMed
  10. Cancer Res. 1977 Sep;37(9):3344-8 - PubMed
  11. Cancer Res. 1982 Aug;42(8 Suppl):3365s-3368s - PubMed
  12. In Vivo. 1987 May-Jun;1(3):173-9 - PubMed
  13. Eur J Cancer. 1976 Dec;12 (12 ):951-8 - PubMed
  14. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1443-50 - PubMed
  15. Pharmacol Ther. 1983;23(2):193-216 - PubMed
  16. J Histochem Cytochem. 1979 Jan;27(1):144-52 - PubMed
  17. Eur J Cancer Clin Oncol. 1986 Jan;22(1):69-75 - PubMed
  18. J Histochem Cytochem. 1977 Jul;25(7):724-9 - PubMed
  19. Steroids. 1978 Dec;32(5):669-80 - PubMed
  20. Cancer Res. 1978 Aug;38(8):2429-33 - PubMed
  21. Cancer Res. 1982 Aug;42(8 Suppl):3378s-3381s - PubMed
  22. J Clin Endocrinol Metab. 1975 Mar;40(3):367-72 - PubMed
  23. Wilehm Roux Arch Dev Biol. 1984 May;193(3):139-148 - PubMed
  24. Cytometry. 1987 Mar;8(2):217-24 - PubMed
  25. Eur J Cancer Clin Oncol. 1986 Jul;22(7):849-56 - PubMed
  26. Cancer Res. 1982 Aug;42(8 Suppl):3369s-3372s - PubMed
  27. Eur J Cancer Clin Oncol. 1986 Apr;22(4):515-25 - PubMed
  28. J Clin Endocrinol Metab. 1979 Aug;49(2):272-7 - PubMed
  29. J Natl Cancer Inst. 1987 May;78(5):993-8 - PubMed
  30. J Steroid Biochem. 1980 Dec;13(12):1427-31 - PubMed
  31. Steroids. 1978 Apr;31(4):463-70 - PubMed
  32. J Natl Cancer Inst. 1986 Jul;77(1):173-8 - PubMed
  33. J Steroid Biochem. 1979 Jun;10(6):623-7 - PubMed
  34. Cancer Res. 1976 Dec;36(12):4610-8 - PubMed
  35. J Histochem Cytochem. 1974 Jul;22(7):569-76 - PubMed
  36. Anticancer Res. 1986 Jul-Aug;6(4):753-9 - PubMed
  37. Cancer Res. 1982 Aug;42(8 Suppl):3274s-3276s - PubMed
  38. Anal Quant Cytol. 1983 Jun;5(2):79-89 - PubMed
  39. J Clin Endocrinol Metab. 1975 Mar;40(3):413-7 - PubMed

Substances

MeSH terms

Publication Types